TYME stock forecast
Our latest prediction for Tyme Technologies, Inc.'s stock price was made on the July 16, 2020 when the stock price was at 1.26$.
In the short term (2weeks), TYME's stock price should outperform the market by 3.89%. During that period the price should oscillate between -10.68% and +18.12%.
In the medium term (3months), TYME's stock price should outperform the market by 24.11%. During that period the price should oscillate between -44.14% and +49.82%.
Get email alertsCreate a solid portfolio with TYME
About Tyme Technologies, Inc.
Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.19$ per share.
The book value per share is 0.22$
Three months stock forecastJuly 16, 2020
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -26M | - | -22M | -0.19 | - | - | 115M | 0.22 | -20M | - | -20M |